Dynamics and source of endothelin-1 and interleukin-6 following coronary reperfusion in patients with acute myocardial infarction

Journal of Nippon Medical School

Volumn 74, Issue 2, 2007, Pages 131-147

  Imaizumi, Takahiro ^a   Nejima, Jun ^a,c   Kiuchi, Kaname ^a   Takeda, Shinhiro ^a,b   Seino, Yoshihiko ^a   Tanaka, Keiji ^a   Takano, Teruo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TSURUMI UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; Coronary reperfusion; Endothelin 1; Hemodynamics; Interleukin 6

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; ENDOTHELIN 1; INTERLEUKIN 6;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY CATHETER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY REPERFUSION; CREATINE KINASE BLOOD LEVEL; FEMALE; HEART MUSCLE NECROSIS; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS CATHETER; MALE; SWAN GANZ CATHETER;

BLOOD VESSELS; ENDOTHELIN-1; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; TIME FACTORS;

EID: 34247579020     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.74.131     Document Type: Article

References (50)

1. Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Miyauchi T, Yanagisawa M, Tomizawa T, et al.: Increased plasma concentrations of endothelin-1 in acute myocardial infarction. Lancet 1989; 2: 53-54.
3. Yasuda M, Kohno M, Tahara A, et al.: Circulating immunoreactive endothelin in ischemic heart disease. Am Heart J 1990; 119: 801-806.
4. Stewart DJ, Kubac G, Costello KB, Cernacek P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991; 18: 38-43.
5. Setsuta K, Seino Y, Tomita Y, Nejima J, Takano T, Hayakawa H: Origin and pathophysiological role of increased endothelin-1 in patients with acute myocardial infarction. Angiology 1995; 46: 557-565.
6. Battistelli S, Billi M, Manasse G, Vittoria A, Roviello F, Forconi S: Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. Angiology 1999; 50: 629-638.
7. Toyo-oka T, Aizawa T, Suzuki N, et al.: Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation 1991; 83: 476-483.
8. Salomone O, Elliot PM, Calvino R, Holt D, Kaski JC: Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. J Am Coll Cardiol 1996; 28: 14-19.
9. Vojacek J, Lisy O, Simek S, et al.: Local changes in plasma endothelin level in the coronary artery immediately after percutaneous transluminal coronary angioplasty. Cardiology 1997; 88: 1-5.
10. Velasco CE, Turner M, Inagami T, et al.: Reperfusion enhances the local release of endothelin after regional myocardial ischemia. Am Heart J 1994; 128: 441-451.
11. Malatino LS, Grassi R, Stancanelli B, et al.: Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty. Am Heart J 1993; 126: 700-702.
12. Montalescot G, Viossat I, Chabrier PE, et al.: Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization. J Am Coll Cardiol 1994; 24: 1236-1241.
13. Miyauchi T, Doi T, Suzuki N, et al.: Plasma endothelin-1 concentrations in the coronary sinus in dogs with artificially induced myocardial infarction. Peptides 1992; 13: 1013-1015.
14. Takeda S, Takano T, Ogawa R: The effect of nasal continuous positive airway pressure on plasma endothelin-1 concentrations in patients with severe cardiogenic pulmonary edema. Anesth Analg 1997; 84: 1091-1096.
15. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Mortin JJ: Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374-1379.
16. Stangl K, Dshietzig T, Richter C, et al.: Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure. Acute effect of vasodilator therapy. Circulation 2000; 102: 1132-1138.
17. Azevedo ER, Stewart DJ, Parker JD: Increased Extraction of endothelin-1 across the failing human heart. Am J Cardiol 2001; 88: 180-182.
18. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M: Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23: 1427-1433.
19. Stewart DJ, Levy RD, Cernacek P, Langleben D: Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.
20. Giaid A, Yanagisawa M, Langleben D, et al.: Expression of endothelin-1 in the lung of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
21. Takeda S, Nakanishi K, Inoue T, Ogawa R: Delayed elevation of plasma endothelin-1 during unilateral alveolar hypoxia without systemic hypoxemia in humans. Acta Anaesth Scand 1997; 41: 274-280.
22. Dupuis J, Cernacek P, Tardif JC, et al.: Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998; 135: 614-620.
23. Saito Y, Nakao K, Mukoyama M, Imura H: Increased plasma endothelin level in patients with essential hypertension. New Engl J Med 1990; 322: 205.
24. Zeiher AM, Goebel H, Schachinger V, Ihling C: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-947.
25. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
26. Verma S, Li SH, Badiwala MV, et al.: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-1896.
27. Tsutamoto T, Wada A, Hayashi M, et al.: Relationship between transcardiac gradient of endothelin-1 and left ventricular remodeling inpatients with first anterior myocardial infarction. Eur Heart J 2003; 24: 346-355.
28. Sakai S, Miyauchi T, Sakurai T, et al.: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93: 1214-1222.
29. Yip Y-K, Wu C-J, Chang H-W, et al.: Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005; 127: 1491-1497.
30. Katayama T, Yano K, Nakashima H, et al.: Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circ J 2005; 69: 654-658.
31. Ito H, Hirata Y, Adachi S, et al.: Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993; 92: 398-403.
32. Kurihara H, Yoshizumi M, Sugiyama T, et al.: Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435-1540.
33. Yamashita J, Ogawa M, Nomura K, et al.: Interleukin 6 stimulates the production of immunoreactive endothelin 1 in human breast cancer cells. Cancer Res 1993; 53: 464-467.
34. Yoshizumi M, Kurihara H, Sugiyama T, et al.: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 1989; 161: 859-864.
35. Seino Y, Setsuta K, Tomita Y, Nejima J, Takano T, Hayakawa H: Increase plasma levels of interleukin-6 and myocardial stunning after coronary reperfusion therapy. Am J Cardiol 1995; 76: 718-720.
36. Ikeda U, Ohkawa F, Seino Y, et al.: Serum interleukin-6 levels become elevated in acute myocardial infarction. J Mol Cell Cardiol 1992; 24: 579-584.
37. Miyao Y, Yasue H, Ogawa H, et al.: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993; 126: 1299-1304.
38. rd. (Bergmeyer HU, ed), 1983; pp 508-539, Verlag Chemie, Weinheim.
39. Wuerzburg U, Hennrich N, Orth HD, et al.: Quantitative determination of creatine kinase isoenzyme catalytic concentrations in serum using immunological methods. J Clin Chem Clin Biochem 1977; 15: 131-137.
40. Verbeke G, Molenberghs G: Lenear mixed models in practice. In A SAS-oriented Approach (Verbeke G, Molenberghs G, eds), 1997; Springer-Verlag, New York.
41. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A: Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991; 69: 370-377.
42. Koyama H, Tabata Y, Nishizawa T, Inoue H, Morii H, Yamaji T: Plasma endothelin levels in patients with uremia. Lancet 1989; 1: 991-992.
43. Dupuis J, Schwab AJ, Simard A, et al.: Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am J Physiol 1999; 277 (Gastrointest Liver Physiol 40): G905-G914.
44. Saito M, Kabazawa N, Imura H: Endothelin in human disease I: essential hypertension, vasospastic angina, acute myocardial infarction and chronic renal failure. In Endothelin (Rubany GM, ed), 1992; pp 209-220, Oxford University Press, New York.
45. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-389.
46. Takahashi A, Xin X, Cai Y, Sakai T, Matsumoto K: Stimulation of interleukin-6 production by endothelin in rat bonemarrow-derived stromal cells. Blood 1994; 84: 2231-2538.
47. Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004; 364: 347-354.
48. O'Connor CM, Gattis WA, Adams KF, et al.: Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol 2003; 41: 1452-1457.
49. Mulder P, Richard V, Derumeaux G, et al.: Selective endothelin-A versus combined endothelin-A / endothelin-B receptor blockade in rat chronic heart failure. Circulation 1997; 96: 1976-1982.
50. Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-355.